Paid Clinical Trials in Lancaster, PA
As of August 2026, 73 paid clinical trials are recruiting in Lancaster, Pennsylvania. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Lancaster offers studies at sites including Lancaster General Hospital for conditions such as Heart Failure, Amblyopia, Neoplasm Metastasis, Non-small Cell Lung Cancer. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Lancaster
Trials by drug in Lancaster
Filter results
Newly added in Lancaster
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
68 clinical trials
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
ELEVATE-HFpEF Clinical Study
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Pan Tumor Rollover Study
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Myriad™ Augmented Soft Tissue Reconstruction Registry
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Top Research Study Locations in Lancaster
Researchers run research studies in Lancaster, PA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Lancaster General Hospital | Abdominal Wound Dehiscence, Advanced Cancer, Anal Fistula | 12 |
| Keystone Urology Specialists | FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration | 8 |
| Lancaster General Hospital - Ann B Barshinger Cancer Institute | Neoplasm Metastasis, Breast Neoplasms, Carcinoma, Transitional Cell | 7 |
| Lancaster General Ann B Barshinger Cancer Institute | Breast Cancer, Depression, Locally Advanced Lung Non-Small Cell Carcinoma | 4 |
| Lancaster General Health | Cancer, Cardiovascular Disease and Lipoprotein(a), Hypertension | 4 |
| Penn Medicine Lancaster General Health | Burnout, Professional, Cardiovascular Diseases, Functional Mitral Regurgitation | 4 |
| Conestoga Eye | Amblyopia | 3 |
| Amish Research Clinic | Diabetes Type 2, Hyperglycemia, Obesity | 2 |
| Penn Medicine Lancaster General | AV Block, Heart Failure, Heart Failure With Reduced Ejection Fraction | 2 |
| US Digestive Health | Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH) | 2 |
| University of Maryland Amish Research Clinic | Diabetes, Ethics, Familial Hypercholesterolemia | 2 |
| Advanced Surgery Center of Lancaster | Lumbar Spinal Stenosis | 1 |
| Ann B Barshinger Cancer Institute | Ovarian Cancer | 1 |
| Ann B. Barshinger Cancer Institute | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | 1 |
| Cardiology Care for Children | Cardiomyopathy | 1 |
| Clinical Trial Site | Transthyretin Amyloidosis With Cardiomyopathy | 1 |
| Lancaster Gen Health | Lumbar Spinal Stenosis | 1 |
| Lancaster General Health - Ann B. Barshinger Cancer Institute | Cervical Cancer, Endometrial Cancer, Uterine Cancer | 1 |
| Lancaster Urology | Castration-Resistant Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Prostate Cancer | 1 |
| Local Institution - 0288 | Non-Small Cell Lung Cancer (NSCLC) | 1 |
| Penn Lancaster General Health Research Institute | Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | 1 |
| Penn Med. Lancaster Gen Hospital | Heart Failure, Obesity | 1 |
| Penn Medicine - Lancaster General Hospital | Metastatic Breast Cancer | 1 |
| Penn Medicine Lancaster General Hospital | Moderate Aortic Valve Stenosis | 1 |
| Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute | Neoplasm Metastasis, Ureteral Neoplasms, Urinary Bladder Neoplasms | 1 |
Active & Upcoming Studies in Lancaster (2026)
Recruiting trials in Lancaster grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (33 active studies)
- Study of Oral MRT-2359 With Apalutamide in Prostate Cancer · Phase 2 · Monte Rosa Therapeutics, Inc
- A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) · Phase 3 · Bristol-Myers Squibb
Cardiovascular (10 active studies)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention · Phase 4 · Duke University
Diabetes & metabolic (3 active studies)
- Pharmacogenetics of Response to Sitagliptin (PRS) · Phase 4 · University of Maryland, Baltimore
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
Mental health & behavior (1 active study)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
Neurology & pain (1 active study)
- MyStroke for Stroke Survivors and Caregivers · University of Pennsylvania
Pediatric (1 active study)
- Vancomycin Reduction Practices (VRP) in the NICU · Children's Hospital of Philadelphia
Common conditions studied in Lancaster
- Heart Failure (4 active studies)
- Amblyopia (3 active studies)
- Neoplasm Metastasis (3 active studies)
- Non-small Cell Lung Cancer (3 active studies)
- Prostate Cancer (3 active studies)
- Breast Cancer (2 active studies)
Leading research sponsors in Lancaster
- AstraZeneca
- Abramson Cancer Center at Penn Medicine
- Bristol-Myers Squibb
- NRG Oncology
- University of Maryland, Baltimore
Frequently asked questions
How many paid clinical trials are currently recruiting in Lancaster?
There are approximately 73 recruiting clinical trials in Lancaster, Pennsylvania listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Lancaster pay participants?
Most recruiting trials in Lancaster compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Lancaster?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Lancaster?
The most common conditions under active study in Lancaster include Heart Failure (4), Amblyopia (3), Neoplasm Metastasis (3), Non-small Cell Lung Cancer (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Lancaster?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Lancaster on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Lancaster?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Lancaster?
Recruiting research sites in Lancaster include Lancaster General Hospital, Keystone Urology Specialists, Lancaster General Hospital - Ann B Barshinger Cancer Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Lancaster right now?
The largest active categories in Lancaster are Cancer & tumors (33), Cardiovascular (10), Diabetes & metabolic (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.